Skyrizi now PBS listed
For Fellows and Trainees
For Health Professionals
Posted 3 months ago
Skyrizi (risankizumab) is now Pharmaceutical Benefits Scheme listed for the treatment of severe chronic plaque psoriasis.
The drug is an interleukin 23 (IL-23) inhibitor and is indicated for treatment in adults who are candidates for phototherapy or systemic therapy.
Please review the Consumer Medicines Information here for further safety information.